An experimental weight-loss pill is showing promising results, helping people drop 13% of their body weight in a three-month period. The results from early clinical trials were presented by Novo ...

A new weight loss pill developed by the maker of Ozempic and Wegovy helped overweight and obese people lose up to 13% of ...

more people are turning to old-school weight loss drugs such as Qsymia and Contrave, which come in pill form but also include ...

All weight loss medications are not created equal ... Qsymia label. U.S. Food and Drug Administration. Contrave label. U.S. Food and Drug Administration. Saxenda label. Novo Nordisk. Novo Nordisk ...

The weight-loss drug Contrave carries a black box warning about suicidal thinking, and another obesity medicine, Qsymia, carries a warning telling patients to stop taking it if they experience ...

Novo Nordisk reported that its new obesity pill led to substantial weight loss in an early study, boosting the company’s ...

It outperformed Orexigen's Mysimba/Contrave weight loss drug, where around a quarter of patients in a phase 3 trial achieved the target. Semaglutide came out top of the analysis, with 63% of ...

Currax Pharmaceuticals CEO George Hampton talks about the demand for the FDA-approved obesity drug Contrave. Demand is growing fast. He is on "Bloomberg Open Interest." Average UK annual salary by ...

The U.S. Food and Drug Administration (FDA ... stop the medication and help you choose a different weight loss treatment. Contrave is a twice-daily medication approved only for adults meeting ...